Clinical Trial Update: A Trial of Observed Long-acting, Anti-HIV Treatment With a Monoclonal CCR5 Antibody (PRO 140) as an Adjunct to a New, Optimized, Oral Antiretroviral Regimen in HIV-infected Injection Drug Users With Viral Rebound and Documented Poor Adherence [Phase 2]

View source ↗

Summary

Phase 2 trial of PRO 140 (leronlimab), a monoclonal CCR5 antibody, as an adjunct to an optimized oral antiretroviral regimen in HIV-infected injection drug user…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• PRO 140 (leronlimab)

Snippet

Sponsor: CytoDyn, Inc. | Conditions: HIV | Phase 2 | Status: WITHDRAWN